Group psychotherapy for adults with mild anxiety and depression
Pilot Randomized Controlled Trial of an Integrative Group Psychotherapy (Terebenin's Method) in Adults with Subclinical and Mild/Moderate Anxiety and Depression
This study is testing a new group therapy method to see if it can help adults with mild anxiety and depression feel better compared to regular treatments.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | S.lab (Soloways) Academic / other |
| Locations | 1 site (Novosibirsk) |
| Trial ID | NCT06863948 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of Terebenin's Method, an integrative group psychotherapy approach, for adults experiencing subclinical and mild to moderate anxiety and depression. The therapy combines elements from psychodrama, family systemic methods, Gestalt therapy, and body-oriented techniques to enhance treatment outcomes. Participants will attend weekly group sessions for eight weeks, with follow-up visits that include saliva sample collection to assess physiological responses. The study aims to determine if this integrative approach can provide better relief from symptoms compared to traditional therapies.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-60 with subclinical, mild, or moderate anxiety and depressive symptoms who are not currently on psychotropic medications.
Not a fit: Patients with severe psychiatric disorders or significant suicidal risk will not benefit from this study.
Why it matters
Potential benefit: If successful, this therapy could offer a novel and effective treatment option for individuals struggling with mild anxiety and depression.
How similar studies have performed: Previous studies have shown that integrative psychotherapeutic approaches can be effective, suggesting potential success for this novel method.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18-60. * Subclinical, mild, or moderate anxiety/depressive symptoms (screened via HADS, BDI-II, STAI). * No current psychotropic medication use or on a stable dose for ≥4 weeks with no planned changes. * Ability to attend weekly group sessions for 8 weeks + follow-up visits, including saliva sample collection. * Provision of written informed consent. Exclusion Criteria: * Severe psychiatric disorders (e.g., schizophrenia, bipolar disorder in a manic phase, major depression with psychotic features). * Significant suicidal risk requiring urgent intervention. * Severe somatic illness impeding participation. * Active substance use disorder unless in stable remission for \>6 months. * Ongoing psychotherapy that could confound results. * Inability to comply with saliva collection (e.g., shift work, severe sleep disturbances).
Where this trial is running
Novosibirsk
- Center for New Medical Technologies — Novosibirsk, Russian Federation (Recruiting)
Study contacts
- Study coordinator: Andrei V Ponomarenko, MD
- Email: dayshadoff@gmail.com
- Phone: +79628316017
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.